Skip to main content
Premium Trial:

Request an Annual Quote

Waters, NIBRT Establish Partnership for Glycan, Biotherapeutic Analysis

NEW YORK (GenomeWeb News) – Waters and the Irish National Institute for Bioprocessing Research and Training said today that they have established a multi-level partnership for the study of biotherapeutic design.

Under the partnership, the two parties have established the Complete Product and Processing Characterization Facility, a center for training scientists in "fit-for-purpose" biopharmaceutical analysis including protein and peptide characterization, as well as educating them on existing and pending US and European drug regulations.

The partnership also establishes NIBRT as a Waters Center of Innovation in the area of glycobiology. NIBRT principal investigator Pauline Rudd will work with Waters' mass spectrometry systems to improve techniques for glycan analysis, a key aspect of biotherapeutic design and processing.

"This partnership will enable NIBRT, with the help of Waters, to provide advanced solutions for the pharmaceutical industry, including protein characterization, N- and O- glycan analysis," NIBRT Interim Director Ian Marison said in a statement.

Financial and other terms of the partnership were not disclosed.

The deal follows on a 2010 agreement between Waters and Rudd's group at NIBRT to develop a database for glycan analysis by ultra performance liquid chromatography.

As reported by GenomeWeb Daily News sister publication ProteoMonitor, that project called for Rudd and NBIRT to build a repository of chromatographic retention times for sets of glycan structures that biopharma companies could use for confirming the structures of glycosylated proteins.

NIBRT maintains and licenses the database, co-marketing it with Waters.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.